A review of the Human Insulin Market Share shows that three global giants—Novo Nordisk, Sanofi, and Eli Lilly—control the vast majority of the global supply. However, the landscape is changing as companies like Biocon and Viatris gain significant ground with biosimilar products. This increased competition is finally starting to drive down prices for the end consumer, particularly in...